Considering the involvement of RANK-L in tumor progression [97] and its presence on OS cell surface [98], in 2020 Punzo and collaborators tested DEN effects, alone and in combination with Doxorubicin, one of the most used anticancer drugs to treat OS, in OS cell line [99,100]. Here, TNFSF11 is linked to neoplasm.